Chimerix Stock News

DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patien

DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patien

DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients

HC Wainwright restated their buy rating on shares of Chimerix (NASDAQ:CMRX) in a report released on Wednesday morning, Price Targets.com reports. They currently have a $24.00 target price on the biopharmaceutical companys stock, up from their prior target price of $21.00. CMRX has been the subject of several other research reports. Zacks Investment Research upgraded []

Brokerages expect Chimerix, Inc. (NASDAQ:CMRX) to report $45.05 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Chimerixs earnings. The highest sales estimate is $90.00 million and the lowest is $110,000.00. Chimerix posted sales of $1.12 million in the same quarter last year, which suggests a positive year over []

Brokerages expect that Chimerix, Inc. (NASDAQ:CMRX) will report earnings per share of ($0.11) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Chimerixs earnings, with the highest EPS estimate coming in at $0.71 and the lowest estimate coming in at ($0.46). Chimerix reported earnings per share of ($0.19) during the []

Chimerix Inc. (NASDAQ:CMRX) price on Friday, December 10, fall -3.37% below its previous days close as a downside momentum from buyers pushed the stocks value to $6.02. A look at the stocks price movement, the close in the last trading session was $6.23, moving within a range at $6.00 and $6.33. The beta value (5-Year Data-Based Insights About Chimerix Inc. (CMRX) Read More »

Chimerix, Inc. (NASDAQ:CMRX) has received an average recommendation of Buy from the six analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on []

Goldman Sachs Group Inc. reduced its stake in Chimerix, Inc. (NASDAQ:CMRX) by 87.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 81,344 shares of the biopharmaceutical companys stock after selling 581,493 shares during the period. Goldman Sachs Group Inc. owned approximately []

Chimerix Inc. (NASDAQ:CMRX) traded at $5.86 at close of the session on Monday, 11/29/21, made a downward move of -0.68% on its previous days price. Looking at the stock we see that its previous close was $5.90 and the beta (5Y monthly) reads 1.44 with the days price range being $5.59 $6.16. In terms Chimerix Inc. (NASDAQ: CMRX) Has Yet To Win Over Analysts? Read More »

Analysts expect Chimerix, Inc. (NASDAQ:CMRX) to report $45.05 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Chimerixs earnings, with the highest sales estimate coming in at $90.00 million and the lowest estimate coming in at $110,000.00. Chimerix reported sales of $1.12 million during the same quarter last []

During the last session, Chimerix Inc. (NASDAQ:CMRX)s traded shares were 0.58 million, with the beta value of the company hitting 1.42. At the end of the trading day, the stocks price was $5.90, reflecting an intraday loss of -5.30% or -$0.33. The 52-week high for the CMRX share is $11.57, that puts it down -96.1 Chimerix Inc. (NASDAQ: CMRX)s -7.09% Loss This Week Just Tells Us Something New Read More »

Chimerix, Inc. (NASDAQ:CMRX) Investment analysts at Wedbush issued their Q4 2021 earnings per share estimates for Chimerix in a note issued to investors on Monday, November 22nd. Wedbush analyst D. Nierengarten anticipates that the biopharmaceutical company will post earnings per share of ($0.22) for the quarter. Wedbush currently has a Outperform rating and a []

California State Teachers Retirement System grew its stake in Chimerix, Inc. (NASDAQ:CMRX) by 12.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,745 shares of the biopharmaceutical companys stock after acquiring an additional 10,987 shares during the period. California State Teachers []